BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...its board including BioMedPartners’ Markus Hosang and Pfizer Ventures’ Michael Baran. Peregrine closes $115M fund Peregrine...
...new fund will continue to invest in early and late stage medical technology startups; previous Peregrine...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

...next quarter. Oncologie acquired the mAb against phosphatidylserine, as well as anti-VEGFR-2 mAb varisacumab, from Avid Bioservices Inc....
...Toll-like receptor 9; VEGFR-2 (KDR/Flk-1) - VEGF receptor 2 Elizabeth S. Eaton, Staff Writer bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen...
BioCentury | Jun 8, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

...compound in China, Hong Kong, Macao, Taiwan and Singapore. The company also acquired bavituximab from Avid Bioservices Inc....
...not reached vs. 12.6 months, HR=0.46, p=0.006). Oncologie Ltd., Cayman Islands Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen...
BioCentury | Jun 7, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

...compound in China, Hong Kong, Macao, Taiwan and Singapore. The company also acquired bavituximab from Avid Bioservices Inc....
...receive immune checkpoint inhibitors (not reached vs. 12.6 months, HR=0.46, p=0.006). Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen...
BioCentury | Feb 23, 2018
Financial News

Avid raises $23M in follow-on

...Contract development and manufacturing company Avid Bioservices Inc. (NASDAQ:CDMO) raised $23.2 million through the sale of 10.3 million...
...company's $3.25 close on Feb. 14, before the offering was proposed. Avid Bioservices Inc. (NASDAQ:CDMO), Tustin, Calif. Shannon Lehnbeuter Avid Bioservices Inc....
BioCentury | Feb 16, 2018
Company News

Oncologie purchases bavituximab from Avid

...Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals...
...phosphatidylserine. As part of the deal, Avid will manufacture bavituximab. In 2016, Avid -- then Peregrine...
...BioCentury March 7, 2016 ). Avid Bioservices Inc. (NASDAQ:CDMO) Tustin, Calif. Oncologie Ltd., Cayman Islands Business: Cancer Shannon Lehnbeuter Avid Bioservices Inc. Oncologie...
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...Inc. until its 2016 acquisition by Grupo Ferrer Internacional S.A. (Barcelona, Spain). Biologics manufacturing company Peregrine...
...is succeeded by Roger Lias, who is president of Peregrine’s contract development and manufacturing subsidiary Avid Bioservices Inc....
BioCentury | Dec 22, 2017
Company News

Management tracks: CRISPR, Hua

...hired Stephen Worsley as SVP of business development. He was VP of business development at Peregrine...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...associated with longer survival in Sutent-treated patients but not in placebo controls. 1771 / 1 Peregrine...
BioCentury | Oct 17, 2016
Clinical News

Bavituximab: Interim Phase III data

...Data were presented at the European Society for Medical Oncology meeting in Copenhagen. In February, Peregrine...
...“sufficient improvement” on the primary endpoint of OS vs. docetaxel alone (see BioCentury, March 7). Peregrine...
Items per page:
1 - 10 of 364
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...its board including BioMedPartners’ Markus Hosang and Pfizer Ventures’ Michael Baran. Peregrine closes $115M fund Peregrine...
...new fund will continue to invest in early and late stage medical technology startups; previous Peregrine...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

...next quarter. Oncologie acquired the mAb against phosphatidylserine, as well as anti-VEGFR-2 mAb varisacumab, from Avid Bioservices Inc....
...Toll-like receptor 9; VEGFR-2 (KDR/Flk-1) - VEGF receptor 2 Elizabeth S. Eaton, Staff Writer bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen...
BioCentury | Jun 8, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

...compound in China, Hong Kong, Macao, Taiwan and Singapore. The company also acquired bavituximab from Avid Bioservices Inc....
...not reached vs. 12.6 months, HR=0.46, p=0.006). Oncologie Ltd., Cayman Islands Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen...
BioCentury | Jun 7, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

...compound in China, Hong Kong, Macao, Taiwan and Singapore. The company also acquired bavituximab from Avid Bioservices Inc....
...receive immune checkpoint inhibitors (not reached vs. 12.6 months, HR=0.46, p=0.006). Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen...
BioCentury | Feb 23, 2018
Financial News

Avid raises $23M in follow-on

...Contract development and manufacturing company Avid Bioservices Inc. (NASDAQ:CDMO) raised $23.2 million through the sale of 10.3 million...
...company's $3.25 close on Feb. 14, before the offering was proposed. Avid Bioservices Inc. (NASDAQ:CDMO), Tustin, Calif. Shannon Lehnbeuter Avid Bioservices Inc....
BioCentury | Feb 16, 2018
Company News

Oncologie purchases bavituximab from Avid

...Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals...
...phosphatidylserine. As part of the deal, Avid will manufacture bavituximab. In 2016, Avid -- then Peregrine...
...BioCentury March 7, 2016 ). Avid Bioservices Inc. (NASDAQ:CDMO) Tustin, Calif. Oncologie Ltd., Cayman Islands Business: Cancer Shannon Lehnbeuter Avid Bioservices Inc. Oncologie...
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...Inc. until its 2016 acquisition by Grupo Ferrer Internacional S.A. (Barcelona, Spain). Biologics manufacturing company Peregrine...
...is succeeded by Roger Lias, who is president of Peregrine’s contract development and manufacturing subsidiary Avid Bioservices Inc....
BioCentury | Dec 22, 2017
Company News

Management tracks: CRISPR, Hua

...hired Stephen Worsley as SVP of business development. He was VP of business development at Peregrine...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...associated with longer survival in Sutent-treated patients but not in placebo controls. 1771 / 1 Peregrine...
BioCentury | Oct 17, 2016
Clinical News

Bavituximab: Interim Phase III data

...Data were presented at the European Society for Medical Oncology meeting in Copenhagen. In February, Peregrine...
...“sufficient improvement” on the primary endpoint of OS vs. docetaxel alone (see BioCentury, March 7). Peregrine...
Items per page:
1 - 10 of 364